Press release
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
–Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications– –In KONFIDENT-S, oral sebetralstat
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n–Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications–\n\n\n–In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks, regardless of long-term prophylaxis mechanism of action–\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom that underscores the critical role of effective on-demand (OD) treatment for HAE attacks among patients receiving long-term prophylaxis (LTP).\n\n\nSebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhibitor for Long-term Prophylaxis: Interim Analysis from KONFIDENT-S was presented by Marc A. Riedl, MD, Professor of Medicine and Clinical Director of the US Hereditary Angioedema Association Center at the University of California, San Diego.\n\n\n\nThe KONFIDENT-S interim analysis, involving 35 participants receiving berotralstat, lanadelumab, or C1 inhibitor (C1-INH), treated 382 attacks with sebetralstat\n\n\n\nMedian time to treatment was 6 minutes overall, ranging from 1 minute (C1-INH) to 20 minutes (berotralstat)\n\n\n\nOne-third of attacks were still mild at time of sebetralstat use\n\n\n\nMedian time to beginning of symptom relief was 1.3 hours\n\n\n\n\"Even with advancements in HAE long-term prophylactic treatments, attacks still occur, highlighting the critical need for easily administered, fast-acting, effective on-demand options,\" said Dr. Riedl. \"These data from KONFIDENT-S show the promise of sebetralstat as an effective oral on-demand option that can complement all major long-term prophylaxis treatments, including those acting through plasma kallikrein inhibition, like lanadelumab and berotralstat.”\n\n\nAdherence to Long-Term Prophylaxis for Hereditary Angioedema and the Impact on On-demand Treatment Claims in the US was presented by Daniel Soteres, MD, MPH, Asthma and Allergy Associates and Research Center, Colorado.\n\n\n\nLess than half (44%) of HAE patients using LTP were adherent based on refill data over 12 months\n\n\n\nNo reduction in OD claims was observed in non-adherent patients (18 pre- and post-LTP; p=0.769)\n\n\n\nOver 12 m...